+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors



Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors



Blood 79(10): 2572-2577



The safety and possible efficacy of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) were evaluated in 40 consecutive patients who received transplants from unrelated donors. rhGM-CSF was administered by 2-hour daily intravenous infusion from day 0 to day 20 or day 27 after the marrow infusion. These patients were compared with 78 historical patients who received transplants from unrelated donors who did not receive rhGM-CSF. The rhGM-CSF-treated patients were older (P = .037) and were treated less frequently in laminar air flow rooms (P = .005) than were control patients. However, the rhGM-CSF-treated group had a higher proportion of "good risk" patients with chronic myelogenous leukemia in chronic phase (P = .006) than did the comparison group (P = .017), rendering comparisons of transplant-related complications not meaningful. rhGM-CSF was well tolerated and did not adversely increase the incidence of graft rejection or increase the incidence and severity of acute graft-versus-host disease. The median day the absolute neutrophil count reached 500/mm3 in patients who received rhGM-CSF was day 21, which was not different from that of historical patients. Nevertheless, the numbers of febrile days and septicemic episodes within the first 28 days in patients who received rhGM-CSF were less than in historical patients. The probability of nonrelapse mortality at 1 year in patients who received rhGM-CSF was 22%. In view of the retrospective nature of the control group, we cannot conclusively determine whether rhGM-CSF administration was beneficial. A prospective, randomized controlled study of rhGM-CSF is required to confirm these suggestive data.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040964480

Download citation: RISBibTeXText

PMID: 1586709


Related references

Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood 77(9): 2065-2071, 1991

Recombinant human non-glycosylated granulocyte-macrophage colony-stimulating factor in allogeneic bone marrow transplantation: double-blind placebo-controlled phase III clinical trial. Japanese Journal of Clinical Oncology 24(4): 205-211, 1994

Influence of recombinant human granulocyte colony-stimulating factor on hematopoietic recovery and outcome following allogeneic bone marrow transplantation from volunteer unrelated donors. Bone Marrow Transplantation 23(10): 983-990, 1999

Administration of recombinant human granulocyte-macrophage colony-stimulating factor to children undergoing allogeneic marrow transplantation: a prospective, randomized, double-masked, placebo-controlled trial. Pediatric Transplantation 4(2): 123-131, 2000

Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation. Blood 81(3): 865, 1993

Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor on neutrophil function following allogeneic bone marrow transplantation. Experimental Hematology 19(9): 868-873, 1991

The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous and allogeneic bone marrow transplantation. Cancer Investigation 11(2): 224-228, 1993

Phase II study of recombinant human granulocyte colony-stimulating factor in children undergoing bone marrow transplantation. Bone Marrow Transplantation 18(Suppl. 2): 121-128, 1996

Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood 79(5): 1359-1365, 1992

Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation. Zhonghua Yi Xue Za Zhi 85(35): 2497-2502, 2005

Recombinant human granulocyte-macrophage colony-stimulating factor accelerates engraftment kinetics after allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia. Haematologica 84(2): 133-137, 1999

Recombinant granulocyte macrophage colony stimulating factor after autologous bone marrow transplantation for relapsed non hodgkin's lymphoma blood and bone marrow progenitor growth studies a phase ii eastern cooperative oncology group trial. Blood 78(3): 830-837, 1991

A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood 83(9): 2707-2714, 1994

A multicenter double blind randomized trial of recombinant human granulocyte macrophage colony stimulating factor gm csf in recipients of allogeneic t cell depleted bone marrow. Bone Marrow Transplantation 5(Suppl. 2): 40, 1990